🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

IQVIA Holdings Inc. IQV SPX

Healthcare · Diagnostics & Research · United States
https://www.iqvia.com
Company Profile ↓
$206.81
+29.15% 1Y
Mkt Cap$34.52B
P/E25.66
P/B4.87
52W High$244.29
52W Low$156.66
Book Value$37.27
EPS (TTM)$8.06

Company Overview

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 22.5%, reflecting efficient use of shareholder capital.

Consistent Profit Growth

Net profit has compounded at 13.1% per year over the last five years.

Reasonable Valuation

Trades at a P/E of 25.7, below the sector median of 25.9.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $16.31B (+5.9% YoY); net profit $1.36B.
  • Trailing 12 Months Year-on-year growth — revenue +8.4%, earnings +15.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR 9.9%, profit CAGR 13.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:9.94%
1 Year:8.40%

Compounded Profit Growth

5 Years:13.13%
1 Year:15.00%

Stock Price Performance

1 Year:+29.15%
6 Months:-14.14%
3 Months:+17.99%
1 Month:+13.97%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 57% of range
$156.66 $244.29
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)66.54 · Neutral
Price Performance
1M+13.97%
3M+17.99%
6M-14.14%
1Y+29.15%
Valuation vs Sector

P/E of 25.66 is below the sector median of 25.88 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 22.5%.
  • Profit CAGR of 13.1% over 5 years.
  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
25.66
Industry PE
25.88
Forward P/E
14.57
PEG Ratio
0.73
Book Value
$37.27
Price to Book
4.87
P/S
1.82
EV/EBITDA
14.84
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
9.94%
Profit 5Y
13.13%
Revenue (YoY)
8.40%
Earnings (YoY)
15.00%

Profitability & Returns

ROCE
10.10%
ROE
22.49%
ROA
5.13%
Profit Margin
8.33%
Op Margin
13.61%
Gross Margin
32.99%
EPS (Latest Qtr)
$1.61
EPS (TTM)
$8.06

Balance Sheet & Liquidity

Debt/Equity
2.55
Quick Ratio
0.66
Current Ratio
0.75
Debt
$16.22B
Total Assets
$29.68B
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
1.08%
Chg in Prom Hold
-
FII / Inst Holding
103.97%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$34.52B
Total Revenue (TTM)
$16.63B
EBITDA
$3.00B
Free Cash Flow
$2.16B
Operating Cash Flow
$2.70B
Shares Outstanding
166.90M
Gross Margin
32.99%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 IQV IQVIA Holdings Inc. SPX 206.81 25.66 $34.52B 0.00% 10.10% 22.49% 9.94% 13.13%
2 LLY Eli Lilly and Company SPX 1,156.63 41.13 $1.03T 0.60% - 107.46% 7.20% 11.41%
3 JNJ Johnson & Johnson SPX 247.02 28.66 $594.63B 2.23% 14.88% 26.42% 2.43% 4.76%
4 ABBV AbbVie Inc. SPX 244.11 119.08 $431.29B 3.04% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPX 418.52 31.54 $380.08B 2.18% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPX 123.61 34.82 $305.29B 2.82% - 18.94% 5.64% 10.01%
7 AZN AstraZeneca PLC NDX 168.37 26.10 $261.12B 1.87% 15.97% 23.48% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPX 535.29 29.40 $198.93B 0.35% 8.14% 13.52% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPX 358.32 24.92 $193.39B 2.80% 18.02% 101.32% 11.77% 5.58%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue --------2.36B2.35B2.47B2.52B2.56B2.57B2.59B2.69B2.68B2.74B2.77B2.90B2.75B2.52B2.79B3.30B3.41B3.44B3.39B3.57B3.54B3.56B3.65B3.73B3.74B3.74B3.81B3.90B3.83B4.02B4.10B4.15B
Gross Profit -----------------562.00M563.00M-547.00M449.00M600.00M-731.00M715.00M727.00M799.00M795.00M812.00M802.00M850.00M862.00M827.00M863.00M915.00M----
Operating Income 143.00M159.00M166.00M178.00M179.00M151.00M168.00M144.00M202.00M126.00M195.00M142.00M183.00M170.00M181.00M207.00M210.00M197.00M204.00M166.00M193.00M62.00M187.00M289.00M342.00M286.00M302.00M495.00M453.00M472.00M471.00M524.00M481.00M506.00M520.00M550.00M496.00M506.00M553.00M514.00M
Net Income 87.00M85.00M110.00M105.00M107.00M87.00M99.00M-178.00M100.00M62.00M88.00M1.03B69.00M61.00M60.00M69.00M58.00M60.00M57.00M16.00M82.00M-23.00M101.00M119.00M212.00M175.00M261.00M325.00M256.00M283.00M289.00M297.00M303.00M288.00M363.00M285.00M249.00M266.00M331.00M274.00M
Diluted EPS 0.680.670.890.850.880.710.82-0.740.430.280.404.790.320.290.290.340.290.300.290.090.42-0.120.520.611.090.901.341.681.341.491.531.591.631.561.971.551.401.541.931.61

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 4.33B4.87B5.10B5.46B5.74B6.82B9.70B10.41B11.09B11.36B13.87B14.41B14.98B15.40B16.31B
Operating Income 345.25M396.44M462.33M590.00M646.00M576.00M665.00M741.00M777.00M731.00M1.39B1.80B1.98B2.20B2.18B
Net Income 241.77M177.55M226.59M357.00M387.00M72.00M1.28B259.00M191.00M279.00M966.00M1.09B1.36B1.37B1.36B
Diluted EPS 2.051.511.772.723.080.475.741.240.961.434.955.727.297.497.84
R&D Expense 9.99M10.43M4.96M5.79M3.34M----------

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -2.32B2.50B3.05B3.30B3.93B21.21B22.86B22.55B23.25B24.56B24.69B25.34B26.68B26.90B29.94B
Total Equity -900.36M-969.60M-1.36B-667.41M-704.06M-564.00M8.63B8.00B6.71B6.00B6.00B6.04B5.76B6.11B6.07B6.50B
Cash & Equivalents 646.62M516.30M567.73M777.00M867.00M977.00M1.20B959.00M891.00M837.00M1.81B1.37B1.22B1.38B1.70B1.98B
Long Term Debt --2.37B2.04B2.28B2.42B7.11B10.12B10.91B11.54B12.38B12.03B12.60B12.96B12.84B13.88B
Total Liabilities --3.86B3.73B4.00B4.26B12.35B14.61B15.60B16.99B18.28B18.65B19.57B20.57B20.83B23.31B
Current Liabilities --1.31B1.48B1.47B1.59B2.71B3.16B3.53B3.94B4.56B5.24B5.58B6.49B6.96B8.34B

Cash Flows (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -----860.00M970.00M1.25B1.42B1.96B2.94B2.26B2.15B2.72B2.65B
Investing Cash Flow -----1.73B-1.19B-810.00M-1.19B-796.00M-2.10B-2.01B-1.60B-1.44B-2.31B
Financing Cash Flow ------2.28B-72.00M-452.00M-276.00M-217.00M-1.24B-329.00M-382.00M-878.00M-150.00M
Share Buybacks 14.32M13.36M6.43M415.00M515.00M1.10B2.62B1.41B949.00M447.00M406.00M1.17B992.00M1.35B1.24B

Ratios (Annual)

Figures in %.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ---------------
Operating Margin % 8.0%8.1%9.1%10.8%11.3%8.5%6.9%7.1%7.0%6.4%10.0%12.5%13.2%14.3%13.4%
Net Margin % 5.6%3.6%4.4%6.5%6.7%1.1%13.2%2.5%1.7%2.5%7.0%7.6%9.1%8.9%8.3%
ROE % -24.9%-13.1%-34.0%-50.7%-68.6%0.8%16.0%3.9%3.2%4.6%16.0%18.9%22.2%22.6%20.9%
ROCE % -33.3%29.4%32.3%27.7%3.1%3.4%3.9%4.0%3.7%7.2%9.1%9.8%11.0%10.1%

Shareholding Pattern

Insiders
1.08%
Institutions
103.97%
Public Float
-

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for IQV

Google News ue, 14 Jul 2026

IQV vs. PEN: Which Stock Is the Better Value Option? - Yahoo! Finance Canada

<a href="https://news.google.com/rss/articles/CBMifEFVX3lxTE1RcUJzNHM4ZXNTSnJtT193UVBfbUs4T3JvelhGWjNzbzV2MjdnUWFEY0hiOEIzVWxINkg4U1IyVG9PNlVRSHpSU2NyNW1nWXFydWRLbURaUkpmN3BsRmFTcTlZMHEwUEtXOXlDc282WDZwNVRuLW1EZC13Z0w?oc=5" target="_blank">…

Google News Sat, 11 Jul 2026

IQV News | IQVIA HOLDINGS INC (NYSE:IQV) - ChartMill

<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE9DQUg2SHR5UlFrMDZQVWU0eGF5OXFWUDF3VElMVGt2X1llNnNac2dqakh3ZjR1aE8tcXhxYW92TVlZTFM1dzJ3X3FJV3BEaktVd1d6S3N2RVFnZw?oc=5" target="_blank">IQV News | IQVIA HOLDINGS INC (NYSE:IQV)</a>&…

Google News Wed, 24 Jun 2026

IQVIA Gains as Investors Reassess Strong Backlog, Raised EPS Outlook | IQV Stock News - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPRlJpamo4S1F6QlhLdHlOc2JHZzYtMWZvemZiRFNpWFpzZXZGVlI3UmNncll4ekpxY1BBMTZCUVVNWU40dUFUOXEzWFBhMkkxdHJDbVpwSlFOWlloYS1mUjQ5YmI1amNlMnE5UEZoakgya2ZLcXVjMWh4UmhPbjZERndKLURJcGRhMVFjaG…

Google News Mon, 13 Jul 2026

IQV Maintained by Mizuho -- Price Target Raised to $230 - GuruFocus

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxNVzlPVUVEeWhOdDVUc0tsR1pzOWRENGxEQlJBVzFsX09QOTc4SHcySlBFdGcxMG1mOXVhTHUyN0pfOXBKRWRRVW5DNVBPX0JOb244cnUtUHowUlB4NkQ5ODctS3d4aXRreVJSVXhhc2l4UUdfMk9wZnZMZEpqekJxcExKRnkxd2pleE9iSk…

Google News ue, 05 May 2026

Why Is IQVIA (IQV) Stock Soaring Today - StockStory

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQUUEyQ3d0SEhhZ3ZldE9SYi1KUjJ0VGFEQms0ek51MDlBQUtjaGEtT3lLOTBqS2RwN1NlTEs1MXRYOVZ6dzdDOEgtRWxELU85OHBhaGttRkw2dFVLbWdsUTAtNnMyTmVtWi0ySU52VHRLOWkwTG5WR2JUcVZscXRqTFNxNk5IUlVSR0t6ST…

Google News Sat, 11 Jul 2026

Did Artisan’s New Stake in IQVIA (IQV) Reframe Its AI and Data Recurring-Revenue Story? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxPT3Y3VWFvUE1LM1ZLVFVrT3pSR0FxcU94N21jdGlzeWpvNWVyOG82ekdOY2ZXWl9hckVadlh0VEYxRWlpdThwV3p4U0RBTG5maF96MzBMcjVmR2Zlal9sTmFlVGcwVTA5ajIzVlNDU0hjR0FpNHd2OWJvc0lWVlNjeHVUZkcyT2gxM0VrdX…

IQV — Frequently Asked Questions

What is the current share price of IQVIA Holdings Inc. (IQV)?

As of 2026-07-15 16:51 PDT, IQVIA Holdings Inc. (IQV) trades at $206.81 on NYSE. Its 52-week range is $156.66 to $244.29.

What is the market capitalisation of IQV?

IQVIA Holdings Inc. (IQV) has a market capitalisation of $34.52B on NYSE.

What is the P/E ratio of IQV?

IQV trades at a trailing price-to-earnings (P/E) ratio of 25.66. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 4.87.

What is the return on equity (ROE) of IQV?

IQV has a return on equity (ROE) of 22.49%. Its return on capital employed (ROCE) is 10.10%.

Is IQV a good stock to buy?

This page provides a data-driven analysis of IQVIA Holdings Inc. (IQV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space